SLCO1A2, SLCO1B1
 and
 SLCO2B1
 Polymorphisms Influences Chloroquine and Primaquine Treatment in
 Plasmodium vivax
 Malaria

Sortica, Vinicius Albuquerque; Lindenau, Juliana Dal-Ri; Cunha, Mariana; Ohnishi, Maria Deise O; Ventura, Ana M. R. S.; Ribeiro-dos-Santos, Ândrea; Santos, Sidney; Guimaraes, Luciano S.P.; Hutz, Mara Helena

doi:10.2217/pgs-2017-0077

Cited by 16 publications

(17 citation statements)

References 57 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study investigated the frequencies of sequence variations in eleven drug-metabolizing enzymes contributing to phase I (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5) and Phase II (COMT, SULT1A1, SULT1A4 and UGT2B7) metabolism of PQ and CQ as well as seven drug transporter genes (ABCB1, ABCA1, ABCC2, ABCC4, ABCG2, SLCO1B1 and SLC25A40) in 51 Thai patients infected with P. vivax. Although the influence of drug-metabolizing enzymes and drug transporters on the efficacy of PQ treatment on P. vivax infection has been studied, 7,14,16,27 their contribution to relapse is still unclear.…”

Section: Discussionmentioning

confidence: 99%

“…ABCB1 is a member of the superfamily of ATP-binding cassette (ABC) transporters like ABCG2. Sortica et al 16 reported that ABCB1 (MDR1, P-gp) T/nonG/T haplotype carriers (3435C>T, 2677G>A/ T and 1236C>T) were associated with lower parasitemia clearance rates over treatment time in a model adjusted for other clinical factors; however, there was no longer statistically significant difference after false discovery rate analysis. The absence of an association between relapse and ABCG2 in this study may be due to the small number of relapse patients and/or inhibitory effects of CQ that seems to be an inhibitor to some ABC transporters.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, in addition to drug-metabolizing enzymes, transporters have been shown to affect PQ efficacy. 15,16 Sortica et al found that SLCO2B1, SLCO1A2 and SLCO1B1 were associated with the clearance of P. vivax in patients treated with PQ and CQ. 16 The MRP transporter, for example, can be inhibited by quinoline derivatives, 17 and Hayeshi et al demonstrated inhibitory effects of several antimalarial drugs to P-glycoprotein (P-gp) mediated transport and reported that both, PQ and chloroquine, inhibit P-gp.…”

Section: Introductionmentioning

confidence: 99%

“…15,16 Sortica et al found that SLCO2B1, SLCO1A2 and SLCO1B1 were associated with the clearance of P. vivax in patients treated with PQ and CQ. 16 The MRP transporter, for example, can be inhibited by quinoline derivatives, 17 and Hayeshi et al demonstrated inhibitory effects of several antimalarial drugs to P-glycoprotein (P-gp) mediated transport and reported that both, PQ and chloroquine, inhibit P-gp. 18 This study aimed to investigate genetic variation in drug-metabolizing enzymes and drug transporters and their association with relapse in Thai patients treated with a PQ/CQ combination regimen.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine

Chamnanphon¹,

Gaedigk²,

Puangpetch³

et al. 2020

PGPM

View full text Add to dashboard Cite

Purpose: Pharmacogenes have an influence on biotransformation pathway and clinical outcome of primaquine and chloroquine which are often prescribed to treat Plasmodium vivax infection. Genetic variation may impact enzyme activity and/or transporter function and thereby contribute to relapse. The aim of the study was to assess allele, genotype frequencies and the association between pharmacogenes variation and primaquine response in Thai patients infected with Plasmodium vivax. Patients and Methods: Fifty-one patients were genotyped for 74 variants in 18 genes by Sequenom MassARRAY ® and Taqman ® SNP Real-Time PCR. Results: SNP frequencies were not significantly different between relapse (n=4) and nonrelapse (n=47) patients. However, the CYP2C19 c.681G>A, the frequency of the A-allele that defines the non-functional CYP2C19*2 haplotype was significantly higher compared to the G-allele (OR=5.14, p=0.021). Patients heterozygous for ABCG2 c.421C>A had a higher odds ratio (OR=8.75, p=0.071) and the frequency of the G-allele of UGT2B7 c.372G>A was higher compared to the A-allele (OR=3.75, p=0.081). CYP2C19, ABCG2 and UGT2B7 emerged as potential high priority genes. Conclusion: Decreased activity of CYP2C19, ABCG2 and UGT2B7 in combination with CYP2D6 intermediate or poor metabolizer status may expose patients to a higher risk of Plasmodium vivax relapse. Further investigations are warranted to substantiate these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine

Chamnanphon¹,

Gaedigk²,

Puangpetch³

et al. 2020

PGPM

View full text Add to dashboard Cite

show abstract

“…Brazilian studies of SLCO1B1 genotype in relation to drugs other than statins reported that renal transplant patients carrying the c.388G allele had lower dose adjusted blood concentration of tacrolimus compared to 388AA carriers, while SLCO1B1 c.521T>C had no effect and significant interaction between SLCO1B1 genotype and gametocytaemia clearance rate in malaria vivax patients treated with chloroquine and primaquine …”

Section: Resultsmentioning

confidence: 99%

Pharmacogenomics research and clinical implementation in Brazil

Rodrigues‐Soares

Suarez‐Kurtz

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

We searched PubMed entries and the Lattes database of Brazilian Pharmacogenetics Network investigators, for pharmacogenetic/genomic (PGx) studies in the Brazilian population, focusing on the drugs and genes included in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. Warfarin was the most extensively studied drug in a PGx context: a genomewide association study targeting warfarin stable dose identified significant signals in VKORC1 and CYP2C9, several PGx dosing algorithms were developed based on these and other genes, and the implications of population admixture on extrapolation of dosing recommendations in the CPIC guidelines were examined. A study in renal transplanted patients disclosed association of CYP3A5*6 and CYP3A5*7 with tacrolimus dosing, which led to addition of these variants to CYP3A5*3 in the CPIC tacrolimus guideline. Studies verified predisposition of HIV-positive carriers of UGT1A1*28 to severe atazanavir-induced hyperbilirubinaemia, intolerance to 5-fluorouracyl in gastrointestinal cancer patients with deleterious DPYD variants, failure of HCV-infected carriers of IFNL3 rs12979860 to obtain a sustained viral response to PEG-IFN-α, and hypersensitivity reactions to abacavir in HIV-positive carriers of HLA-B*57:01. No prospective analyses of drug therapy outcomes or cost-effectiveness assessments of PGx-guided therapy were found. In conclusion, the limited adoption of PGx-informed drug prescription in Brazil reflects combination of recognized barriers to PGx implementation worldwide plus factors specific to the Brazilian population. The latter include rarity/absence of genetic variants on which international PGx guidelines are based (eg HLA-B*15.02 for phenytoin and carbamazepine) and the caveat of extrapolating to the admixed Brazilian population, guidelines based on categorical variables, such as continental ancestry (eg warfarin guidelines), "race" or ethnicity.

show abstract

Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials

Audu

Petagine²,

Idowu³

et al. 2022

Biomarkers in Toxicology

View full text Add to dashboard Cite

SLCO1A2, SLCO1B1 and SLCO2B1 Polymorphisms Influences Chloroquine and Primaquine Treatment in Plasmodium vivax Malaria

Abstract: The present work presents the first pharmacogenetic report of an association between chloroquine/primaquine responses with OATP transporters.

Cited by 16 publications

References 57 publications

<p>Pharmacogene Variation in Thai <em>Plasmodium vivax</em> Relapse Patients Treated with a Combination of Primaquine and Chloroquine</p>

<p>Pharmacogene Variation in Thai <em>Plasmodium vivax</em> Relapse Patients Treated with a Combination of Primaquine and Chloroquine</p>

Pharmacogenomics research and clinical implementation in Brazil

Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials

Contact Info

Product

Resources

About